Candidate antigen | Positive sera/total tested | Ig Class | Method | Reference |
---|---|---|---|---|
Myelin proteins | ||||
P0 | 6/21 4/21 | IgG | Western blotting IF on normal nerve | 113 |
6/32 | IgG (3), IgA (3) | Western blotting | 114 | |
6/36* | IgG | ELISA | 115 | |
5/32 0/32 | IgM IgG | ELISA | 116 | |
7/30* | IgG | ELISA | 117 | |
0/20* | ELISA | 118 | ||
1/24* | Western blotting | 119 | ||
3/40* 2/40* | IgG IgM | ELISA | 120 | |
P2 | 11/32* 4/32* | IgM IgG | ELISA | 116 |
4/36* | IgG | ELISA | 115 | |
4/30 | IgG | ELISA | 117 | |
3/20* | ELISA | 118 | ||
PMP22 | 3/30* | IgG | ELISA | 117 |
0/24* | Western blotting | 119 | ||
7/17 6/17 | Ig (3), IgM (3), pan Ig (1) | ELISA Western blotting | 121 | |
3/6* | Western blotting | 122 | ||
Cx32 | 1/24* | Western blotting | 119 | |
MBP | 2/40* | IgG | ELISA | 120 |
Nodal antigens | ||||
Neurofascin 155 | 4/61 | IgG4 | ELISA | 123 |
5/117 | IgG4, IgG3; IgM, IgA | ELISA | 124 | |
CIDP 0/16* CCPD 5/7 CIDP 4/16* CCPD 6/7 | IgG | Cell-based assay ELISA | 125 | |
Neurofascin 186 | 1/50* | IgG | Cell-based assay | 126 |
0/117* | ELISA | 124 | ||
Contactin-1 | 3/46† | IgG | Cell-based assay | 127 |
1/50* | IgG | Cell-based assay | 126 |
*Frequency not significantly higher than in healthy controls or other neuropathy controls.
†Contactin-1/caspr-1 in one patient.
CCPD, combined central and peripheral demyelination; IF, immunofluorescence.